---

title: "Low-Dose naltrexone restored TRPM3 ion channel function in natural killer cells from long COVID patients"
tags:
- üß™ Biomarker
- ‚≠ê Landmark
- üíä Treatment
created: '2025-05-19'
published: '2025-05-19'

---


<details>
<summary>Sasso et al. (2025)</summary>

- **Authors:** Etianne Martini Sasso, Natalie Eaton-Fitch, Peter Smith, Katsuhiko Muraki, Sonya Marshall-Gradisnik.
- **Institutes:** The National Centre for Neuroimmunology and Emerging Diseases, Griffith University; Consortium Health International for Myalgic Encephalomyelitis, Griffith University; School of Pharmacy and Medical Sciences, Griffith University; Queensland Allergy Services; Laboratory of Cellular Pharmacology, School of Pharmacy, Aichi-Gakuin University.
- **Publisher:** Frontiers in Molecular Biosciences
- **Link:** [DOI](https://doi.org/10.3389/fmolb.2025.1582967)

</details>


## Summary

This research provides a direct biological mechanism for why LDN may be effective for long COVID. It suggests that LDN works by fixing a fundamental problem in the "calcium gates" (TRPM3 channels) of immune cells, which are known to be faulty in long COVID and ME/CFS. By restoring normal calcium flow, LDN may help normalize immune function and other cellular processes. This finding is significant because it validates a specific biological target for LDN, strengthening the scientific rationale for its use in treating this condition.

## What was researched?

This study investigated whether low-dose naltrexone (LDN) üíä could correct a specific cellular dysfunction‚Äîfaulty TRPM3 ion channels‚Äîin the natural killer (NK) cells of patients with long COVID.

## Why was it researched?

Dysfunctional TRPM3 ion channels are linked to long COVID, causing reduced calcium influx, which harms cellular processes. Since accumulating evidence suggests LDN might help long COVID patients, researchers wanted to see if its benefit was linked to fixing this specific ion channel problem.

## How was it researched?

This was a laboratory study comparing 27 participants. Researchers isolated NK cells from nine healthy controls, nine individuals with long COVID, and nine individuals with long COVID who were being treated with LDN (3‚Äì4.5 mg/day). They then used electrophysiological experiments to measure and compare the TRPM3 ion channel function among the three groups.

## What has been found?

The study found that long COVID patients treated with LDN have restored TRPM3 ion channel function. There was no significant difference in TRPM3 currents between the LDN-treated long COVID patients and the healthy controls. This result also validates previous reports that untreated long COVID patients do have significant TRPM3 dysfunction.

## Discussion

The authors' discussion states that these findings support LDN as a potentially beneficial treatment for long COVID. They conclude that the mechanism involves restoring TRPM3 ion channel function, which in turn reestablishes the adequate calcium ($Ca^{2+}$) influx necessary for normal cellular processes.

## Conclusion & Future Work

The primary conclusion is that LDN treatment appears to reverse a key pathological feature (TRPM3 dysfunction) in the NK cells of long COVID patients, making their cells indistinguishable from healthy controls in this assay. (The provided text does not outline specific future work.)
